Norris Medicines Complete Financial Statements
In FY2026, Norris Medicines (NORRIS) reported revenue ₹8 Cr, net profit ₹0 Cr and EPS ₹-0.28. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Also explore Norris Medicines share price performance to track price trends across different timeframes.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
NORRIS Revenue, Net Profit & EBITDA — Year-on-Year Growth
NORRIS YoY (March 2025 vs March 2026) — revenue +33.3%, net profit +100.0%, expenses +16.7%. Analyse NORRIS shareholder distribution to track promoter, FII and institutional holdings.
NORRIS Income Statement — Revenue, EBITDA & Net Profit
Norris Medicines revenue ₹8 Cr, EBITDA ₹1 Cr, net profit ₹0 Cr, EPS ₹-0.28 (2026). For live price, earnings ratios and company overview, see Norris Medicines share price screener.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 6 | 6 | 8 | 10 | 12 | 8 | 16 | 14 | 21 | 19 | 19 |
| Expenses | 7 | 6 | 6 | 7 | 10 | 14 | 10 | 17 | 16 | 21 | 18 | 17 |
| EBITDA | 1 | 0 | 0 | 1 | 0 | -2 | -2 | -1 | -2 | 0 | 1 | 2 |
| Operating Profit Margin % | 8.00% | -5.00% | -3.00% | 11.00% | -1.00% | -14.00% | -27.00% | -4.00% | -14.00% | 0.00% | 4.00% | 9.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 0 | -1 | -1 | -1 | -2 | -4 | -4 | -2 | -3 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 1 | 1 | 1 | -1 | 0 | -1 | 0 | 0 | 1 |
| Net Profit | 0 | -1 | -1 | -2 | -3 | -5 | -3 | -2 | -3 | -1 | 0 | -1 |
| Earnings Per Share (₹) | -0.28 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | -2.84 | -1.68 | -2.51 | -0.77 | 0.04 | -1.04 |
NORRIS Balance Sheet — Assets, Liabilities & Shareholders' Equity
NORRIS total assets ₹14 Cr, total equity ₹-15 Cr, total liabilities ₹ Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 14 | 14 | 14 | 14 | 20 | 21 | 20 | 21 | 22 | 18 | 18 |
| Current Assets | 6 | 6 | 5 | 4 | 8 | 7 | 7 | 8 | 9 | 7 | 7 |
| Fixed Assets | 5 | 6 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 8 | 9 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 9 | 8 | 7 | 7 | 12 | 12 | 12 | 11 | 12 | 10 | 10 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 19 | 19 | 18 | 18 | 16 | 15 | 11 | 8 | 8 | 8 | 8 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | -15 | -14 | -12 | -11 | -7 | -3 | 0 | 2 | 5 | 5 | 5 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | -25 | -24 | -22 | -21 | -17 | -12 | -10 | -8 | -5 | -5 | -5 |
NORRIS Cash Flow Statement — Operating, Investing & Financing
Norris Medicines operating cash flow ₹1 Cr, investing ₹0 Cr, financing ₹-1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 0 | 1 | -1 | 1 | -3 | -2 | 1 | -1 | 1 | -1 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | -1 |
| Financing Activities | -1 | 0 | -1 | 1 | -1 | 3 | 2 | -1 | 3 | -1 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |